Chapter 5 · What's in a Name?

His mother called at 8:04 AM on a Saturday. Mark knew the time because it was glowing on the nightstand in that accusatory way phone screens glow when someone is calling too early. Karen Chen did not call before nine on weekends unless something was wrong — or unless she'd been reading.

He answered with his eyes still closed. "Hey, Mom."

"Did you read the article I sent you?" No preamble. No how are you. Just the question, delivered in the tone she reserved for things she considered urgent — leaking roofs, expired medications, forwarded health articles from the internet.

"I haven't been awake long enough to read anything."

"It's about NAFLD, Mark. Your condition. It says —" she paused, and he could hear the rustle of paper, which meant she'd printed the article, which meant this was serious — "it says it's a silent killer. That people don't know they have it until the damage is irreversible. That it leads to cirrhosis and liver failure and —"

"Mom." He sat up. Beside him, Priya shifted and pulled the blanket over her head — a practiced response to the sound of Karen Chen's voice at volume. "Mom, slow down. When was this article published?"

"What does that matter?"

"When was it published?"

A pause. More rustling. "2018."

Mark exhaled and swung his legs off the bed. The floor was cold under his feet. He padded to the kitchen, closing the bedroom door softly behind him. "That article is six years old. The science has changed. The terminology has changed. Half of what that article is telling you has been revised."

"Is that what your doctor said, or is that you being optimistic?" His mother's voice carried the specific sharpness of someone who loved him enough to argue. "Because I'm reading another one now, and it says people with this need liver transplants. Did your doctor mention a transplant?"

"No. Not even close." Mark filled a glass of water and drank half of it. "My FIB-4 score is 0.68, which puts me in the lowest risk category. My liver isn't scarred. We caught this early."

"What's a FIB-4?"

"It's a calculation — age, AST, ALT, platelets. It estimates fibrosis risk. Anything under 1.30 means you're almost certainly fine. I'm at 0.68." He leaned against the counter. "But Mom, there's something else I want to tell you. Something that might actually help put this in perspective."

"What?"

"They renamed the disease. Last year. It's not called NAFLD anymore."

The silence on the other end had texture — the particular quality of a retired librarian encountering a recatalogued entry. His mother had spent thirty-two years at the Houston Public Library system, and she processed information the way she'd processed returns: methodically, with a quiet intensity that most people mistook for calm.

"What do they call it now?"

"MASLD. Metabolic Dysfunction-Associated Steatotic Liver Disease. And the inflammatory version — what used to be called NASH — is now called MASH."

"Those are terrible acronyms."

Mark almost laughed. "Maybe. But they're better than the old ones. NAFLD stood for Non-Alcoholic Fatty Liver Disease. Think about that for a second. The name defined the disease by what it wasn't — non-alcoholic. And then it called the liver fatty. So the two things patients heard were: we don't know why you have this, but your liver is fat."

His mother was quiet. He pressed on.

"The new name flips that. MASLD says: this is metabolic. This is about insulin resistance, about how your body processes glucose, about metabolic dysfunction at a cellular level. It's not a character judgment. It's a biological description. And biological problems have biological solutions."

"Metabolic dysfunction," his mother repeated slowly. "That sounds like something a doctor can fix."

"Exactly. That's the whole point of the rename. Fatty liver sounds like a failure. Metabolic dysfunction sounds like a systems problem. And systems problems have solutions."

There was a long pause. Mark could hear his mother's clock ticking in the background — the old mantel clock from her house in Houston that she'd had since before he was born.

"I'm glad they changed it," she said finally. "The old name made me picture something — I don't know. Something broken. Something you couldn't come back from."

"You can come back from this, Mom. That's what the science says. At my stage, it's almost entirely reversible."

"You sound like you believe that now."

He thought about it. Two weeks ago, sitting in his car after Dr. Kim's office, he hadn't believed anything except the weight of the diagnosis. A week ago, staring at the FIB-4 result on Dr. Nguyen's screen, he'd started to believe the numbers. And now, standing in his kitchen in bare feet, explaining the etymology of a disease to his mother, he believed something else: that the words people used to describe a problem shaped whether it felt solvable.

"Yeah," he said. "I think I do."

"Good." His mother's voice softened into the register she used for important things. "You've always been good at solving problems, Mark. Even the ones that scare you. Especially those."

After they hung up, Mark stood at the counter for a while, holding his empty glass. The kitchen was quiet. Morning light came through the window above the sink, catching the dust motes in the air. He felt something settle — not the absence of worry, but the rearrangement of it into something he could carry.

The medical world had looked at this disease — a disease that affected a third of the planet — and decided that the name itself was part of the problem. Not just imprecise. Harmful. The old terminology had baked a judgment into the diagnosis. Non-alcoholic meant: we're telling you what you don't have, which tells you nothing about what you do have. Fatty meant: this is about excess, about indulgence, about a body that stores what it shouldn't. The shame was structural, built into the letters of the acronym.

The new names dismantled that structure. MASLD said: your metabolism is dysregulated. MASH said: there's inflammation on top of that dysregulation. Both pointed to biology, not behavior. Both implied a mechanism that could be understood and reversed, not a moral condition that required penance.

It mattered. Mark could feel how much it mattered in the difference between what his mother had felt reading the 2018 article — silent killer, fatty liver, transplant — and what she'd felt hearing him say metabolic dysfunction. The first set of words produced panic. The second produced a question: How do we fix it?

---

That evening, after the kids were in bed and Priya was reading in the living room, Mark opened his laptop at the kitchen table. He wasn't researching tonight. He was auditing.

He opened every health app he'd downloaded since the diagnosis and looked at one thing: what terminology did it use?

The liver tracking app he'd been entering his labs into said "MASLD" throughout. Its educational content referenced the 2023 consensus. It explained the name change in its FAQ. Mark felt a quiet satisfaction — like discovering that the mechanic you'd chosen actually read the latest service bulletins.

Another app, one he'd downloaded in the first panicked days after diagnosis, was called "FattyLiver Tracker." He opened it. The interface looked like it hadn't been updated since 2019. Every screen said "NAFLD." The dietary recommendations mentioned avoiding red meat and eating more whole grains — not wrong, exactly, but generic in a way that suggested the developers had copied a WebMD article and moved on.

He deleted it.

He found a third app — newer, built specifically around the MASLD framework — that included a module explaining the shift from old to new terminology. It walked through the SLD umbrella, the four subcategories, the reasoning behind the consensus. It felt like the difference between a textbook from this year and one from a decade ago. Both might contain true statements, but only one was working from the current map.

Mark closed the laptop and sat in the quiet kitchen. He was developing a heuristic, he realized — a simple test for whether a health resource deserved his trust. If it used 2023 terminology, it was probably current on everything else. If it was still saying NAFLD in 2024, it was probably still thinking in 2018 frameworks. The words were a signal. The nomenclature was a filter.

A small thing. But Mark was learning that small things — the right name, the right score, the right framing — were the difference between a diagnosis that crushed you and one you could work with.